Ad is loading...
RZLT
Price
$5.29
Change
-$0.31 (-5.54%)
Updated
Nov 15 closing price
80 days until earnings call
URGN
Price
$11.19
Change
-$0.67 (-5.65%)
Updated
Nov 15 closing price
116 days until earnings call
Ad is loading...

RZLT vs URGN

Header iconRZLT vs URGN Comparison
Open Charts RZLT vs URGNBanner chart's image
Rezolute
Price$5.29
Change-$0.31 (-5.54%)
Volume$441.41K
CapitalizationN/A
UroGen Pharma
Price$11.19
Change-$0.67 (-5.65%)
Volume$546.11K
CapitalizationN/A
RZLT vs URGN Comparison Chart
Loading...
RZLT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RZLT vs. URGN commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RZLT is a StrongSell and URGN is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (RZLT: $5.29 vs. URGN: $11.19)
Brand notoriety: RZLT and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RZLT: 111% vs. URGN: 88%
Market capitalization -- RZLT: $295.86M vs. URGN: $472.21M
RZLT [@Biotechnology] is valued at $295.86M. URGN’s [@Biotechnology] market capitalization is $472.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RZLT’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • RZLT’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, RZLT is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RZLT’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 3 bullish TA indicator(s).

  • RZLT’s TA Score: 3 bullish, 5 bearish.
  • URGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both RZLT and URGN are a bad buy in the short-term.

Price Growth

RZLT (@Biotechnology) experienced а -5.20% price change this week, while URGN (@Biotechnology) price change was -7.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

RZLT is expected to report earnings on Feb 05, 2025.

URGN is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($472M) has a higher market cap than RZLT($296M). RZLT YTD gains are higher at: 432.998 vs. URGN (-25.400). RZLT has higher annual earnings (EBITDA): -57.32M vs. URGN (-94.89M). URGN has more cash in the bank: 241M vs. RZLT (13.2M). RZLT has less debt than URGN: RZLT (2.37M) vs URGN (98.2M). URGN has higher revenues than RZLT: URGN (85M) vs RZLT (0).
RZLTURGNRZLT / URGN
Capitalization296M472M63%
EBITDA-57.32M-94.89M60%
Gain YTD432.998-25.400-1,705%
P/E RatioN/AN/A-
Revenue085M-
Total Cash13.2M241M5%
Total Debt2.37M98.2M2%
FUNDAMENTALS RATINGS
RZLT vs URGN: Fundamental Ratings
RZLT
URGN
OUTLOOK RATING
1..100
899
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3480
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RZLT's Valuation (35) in the null industry is somewhat better than the same rating for URGN (77) in the Biotechnology industry. This means that RZLT’s stock grew somewhat faster than URGN’s over the last 12 months.

RZLT's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that RZLT’s stock grew similarly to URGN’s over the last 12 months.

RZLT's SMR Rating (96) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that RZLT’s stock grew similarly to URGN’s over the last 12 months.

RZLT's Price Growth Rating (34) in the null industry is somewhat better than the same rating for URGN (80) in the Biotechnology industry. This means that RZLT’s stock grew somewhat faster than URGN’s over the last 12 months.

RZLT's P/E Growth Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that RZLT’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RZLTURGN
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
87%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
RZLT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNLVX21.05-0.07
-0.33%
Dunham Large Cap Value N
LMGNX65.43-0.82
-1.24%
ClearBridge International Growth I
SLLAX14.91-0.19
-1.26%
SEI Small Cap F (SIMT)
BDFFX31.37-0.58
-1.82%
Baron Discovery Retail
SHPAX20.14-0.50
-2.42%
Saratoga Health & Biotechnology A

RZLT and

Correlation & Price change

A.I.dvisor tells us that RZLT and RLAY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RZLT and RLAY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RZLT
1D Price
Change %
RZLT100%
-5.54%
RLAY - RZLT
32%
Poorly correlated
-8.84%
EDSA - RZLT
27%
Poorly correlated
-4.55%
URGN - RZLT
27%
Poorly correlated
-5.65%
ABEO - RZLT
25%
Poorly correlated
-1.51%
VINC - RZLT
24%
Poorly correlated
-1.57%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-5.65%
CYYNF - URGN
38%
Loosely correlated
N/A
SPRB - URGN
32%
Poorly correlated
-5.83%
ORMP - URGN
28%
Poorly correlated
-4.50%
RZLT - URGN
28%
Poorly correlated
-5.54%
GOSS - URGN
27%
Poorly correlated
-3.88%
More